Clinical Trial Detail

NCT ID NCT04099836
Title Atezolizumab and Bevacizumab in Epidermal Growth Factor Receptor (EGFR) Mutant Non?Small Cell Lung Cancer in Patients With Progressive Disease After Receiving Osimertinib
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Duke University
Indications

lung non-squamous non-small cell carcinoma

Therapies

Atezolizumab + Bevacizumab

Age Groups: senior adult

No variant requirements are available.